Nuvectis Pharma Inc
For the period ended Dec 31, 2023. Filed Mar 5, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 5, 2024
NVCT$21.08+0.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets as of December 31, 2023 and 2022
BALANCE SHEETS
| | | | | |
|---|---|---|---|---|
| · · December 31, | ||||
| | 2023 | 2022 | ||
| Assets | | | | |
| CURRENT ASSETS: | ||||
| Cash and cash equivalents | 19,126 | 19,993 | ||
| Other current assets | 59 | 412 | ||
| TOTAL CURRENT ASSETS | 19,185 | 20,405 | ||
| | | | | |
| TOTAL ASSETS | 19,185 | 20,405 | ||
| | | | | |
| Liabilities and Shareholders’ Equity | ||||
| | | | | |
| CURRENT LIABILITIES | | | | |
| Accounts payables | 2,771 | 2,910 | ||
| Payable offering costs | — | 450 | ||
| Accrued liabilities | 415 | 445 | ||
| Employee compensation and benefits | 3,798 | 2,381 | ||
| TOTAL CURRENT LIABILITIES | 6,984 | 6,186 | ||
| TOTAL LIABILITIES | 6,984 | 6,186 | ||
| | | | | |
| | | | | |
| Common Shares, $0.00001 par value – 60,000,000 shares authorized as of December 31, 2023, and December 31, 2022, respectively, 17,418,886, and 15,190,720 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively | | * | | * |
| Additional paid in capital | 66,446 | 46,204 | ||
| Accumulated deficit | (54,245) | (31,985) | ||
| TOTAL SHAREHOLDERS’ EQUITY | 12,201 | 14,219 | ||
| TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY | 19,185 | 20,405 | ||
*Represent amount lower than $1,000 USD.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.